From the perspective of possible antiviral and antibacterial activity of vanadium‐based complexes, we report the synthesis of new Schiff base ligand (L4) and a new Schiff‐base‐vanadium complex (C2). Both the ligand and the complex were characterized by Fourier transform infrared spectroscopy and Nuclear magnetic resonance techniques. Single‐crystal X‐ray Diffraction analysis has been used to confirm the structure of ligand L4 and complex C2. In addition, L1–4 and C1–3 were tested for their antibacterial effects against Escherichia coli and Staphylococcus aureus. Among the compounds, L2 demonstrated the most potent inhibition of both bacteria, exhibiting the lowest values for minimum inhibitory concentration (CMI) and minimum bactericidal concentration (CMB) (CMI = 0.16, CMB = 0.31 against E. coli, and CMI = CMB = 0.16 against S. aureus). Additionally, L2 produced the largest inhibition zones with diameters of 15.5 ± 0.15 against E. coli and 14.5 ± 0.04 against S. aureus. Furthermore, the antiviral efficacy of L1, L2, L4, C1, C2, and C3 against RNA viruses was assessed. C2 and C3 exhibited the most potent antiviral activity among the tested compounds.
Read full abstract